| Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. | |
| | |
MedLine Citation:
|
PMID: 22564835 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Detailed oseltamivir pharmacokinetics have yet to be reported in neonates and infants; this group is at high risk of serious influenza-associated complications. Extrapolation of doses from older patients is complicated by rapid organ and drug-metabolizing enzyme maturation. A pharmacokinetic study has been conducted during an influenza A(H1N1) outbreak in a neonatal intensive care unit. Each included patient provided 4 samples for oseltamivir and 4 samples for its active metabolite oseltamivir carboxylate. A population pharmacokinetic model was developed with NONMEM. Allometric weight scaling and maturation functions were added a priori to scale for size and age based on literature values. Nine neonates and infants were recruited. A physiologically parameterized pharmacokinetic model predicted typical day 1 area under the curve (AUC(0-12)) values of 1,966 and 2,484 μg · h/liter for neonates and infants of ≤ 37 weeks of postmenstrual age (PMA) and >37 weeks of PMA treated with 1 mg/kg of body weight and 2 mg/kg, respectively. The corresponding steady-state AUC(0-12) values were 3,670 and 4,559 μg · h/liter. Premature neonates treated with 1 mg/kg and term babies treated with 2 mg/kg should have average oseltamivir carboxylate concentrations in a range similar to that for adults treated with 75 mg, corresponding to >200-fold above the half-maximal inhibitory concentration (IC(50)) value for influenza A(H1N1) from the start of therapy. |
| | |
Authors:
|
Joseph F Standing; Angela Nika; Vasileios Tsagris; Ioannis Kapetanakis; Helena C Maltezou; Dimitris A Kafetzis; Maria N Tsolia |
Related Documents
:
|
22355365 - Evaluation of cause of deaths' validity using outcome measures from a prospective, popu... 17946115 - Relation between wavelet-biopotential likeness and wavelet compression of biopotential ... 7619365 - Advances in cardiopulmonary resuscitation. 17915275 - Immunohistochemical detection of matrix metalloproteinase-1 in the periodontal ligament... 17869235 - Goal attribution to inanimate agents by 6.5-month-old infants. 8948005 - On the nature and consequences of early loss. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2012-05-07 |
Journal Detail:
|
Title: Antimicrobial agents and chemotherapy Volume: 56 ISSN: 1098-6596 ISO Abbreviation: Antimicrob. Agents Chemother. Publication Date: 2012 Jul |
Date Detail:
|
Created Date: 2012-06-15 Completed Date: 2012-10-17 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 0315061 Medline TA: Antimicrob Agents Chemother Country: United States |
Other Details:
|
Languages: eng Pagination: 3833-40 Citation Subset: IM |
Affiliation:
|
Infectious Diseases and Microbiology Unit, University College London, Institute of Child Health, London, United Kingdom. j.standing@ucl.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antiviral Agents
/
pharmacokinetics*,
therapeutic use* Disease Outbreaks Female Humans Infant, Newborn Influenza A Virus, H1N1 Subtype / drug effects, pathogenicity* Influenza, Human / drug therapy* Intensive Care Units Male Oseltamivir / pharmacokinetics*, therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
G1002305//Medical Research Council |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Oseltamivir |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Substrate spectrum extension of PenA in Burkholderia thailandensis with a single amino acid deletion...
Next Document: Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptibl...